FdaApplication
BLA 125769
Identifiers
- fda_app_no: BLA125769
Properties
| Property | Value |
|---|---|
| applicant_name | Pfizer Inc. |
| application_type | BLA |
| approval_date | 2023-05-31 |
Revenue by product
ABRYSVO
| Period | Revenue |
|---|---|
| Q2 2026 | $208.0M |
| Q1 2026 | $180.0M |
| Q3 2025 | $279.0M |
| Q2 2025 | $143.0M |
| Q1 2025 | $131.0M |
| Q3 2024 | $356.0M |
| Q2 2024 | $56.0M |
| Q1 2024 | $145.0M |
| Q4 2023 | $515.0M |
| Q3 2023 | $375.0M |
| Q2 2023 | $0.0M |
| Q1 2023 | $0.0M |
| Q4 2022 | $0.0M |
| Q3 2022 | $0.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| ABRYSVO | — | 120UG | Injection |
1 product